Patent intelligence · US
US 11034705
Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
Patent details — US 11034705
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 15, 2021
- Expiration
- Jun 10, 2041
- Applicant
- NIKANG THERAPEUTICS, INC.
- Claims
- 58
- CPC classes
- A61K, A61K31/5383, A61P, A61P35/00
Quick answer
US 11034705 (Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors) is held by NIKANG THERAPEUTICS, INC.. Status: granted. Granted Jun 15, 2021. Expires Jun 10, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- NIKANG THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 58
- CPC classes
- A61K, A61K31/5383, A61P, A61P35/00
More from NIKANG THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12415779
Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
granted -
US 12391642
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12331026
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
granted -
US 12264167
Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
granted -
US 12171741
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12077506
Indane derivatives as hypoxia inducible factor-2(α) inhibitors
granted -
US 11939303
Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
granted -
US 11753366
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted
Frequently asked questions
What is US patent 11034705?
US 11034705 (Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors) is held by NIKANG THERAPEUTICS, INC.. Status: granted. Granted Jun 15, 2021. Expires Jun 10, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11034705?
NIKANG THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 11034705 expire?
Our index shows an expiration date of Jun 10, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.